Curis, Inc. (NASDAQ:CRIS) saw an uptick in trading volume on Thursday after the company announced better than expected quarterly earnings. 12,150,278 shares traded hands during trading, an increase of 564% from the previous session’s volume of 1,829,597 shares.The stock last traded at $0.74 and had previously closed at $0.57.
The biotechnology company reported ($0.05) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.09) by $0.04. The firm had revenue of $3.26 million for the quarter, compared to analysts’ expectations of $2.03 million. Curis had a negative return on equity of 261.66% and a negative net margin of 538.66%. During the same period in the prior year, the business earned ($0.08) EPS.
Separately, Zacks Investment Research cut Curis from a “hold” rating to a “sell” rating in a report on Friday, November 10th. Two equities research analysts have rated the stock with a sell rating, one has assigned a hold rating and three have given a buy rating to the company’s stock. The company currently has a consensus rating of “Hold” and an average price target of $6.50.
Institutional investors have recently bought and sold shares of the business. First Eagle Investment Management LLC raised its position in Curis by 10.4% in the 3rd quarter. First Eagle Investment Management LLC now owns 26,508,672 shares of the biotechnology company’s stock valued at $39,498,000 after buying an additional 2,500,000 shares during the last quarter. BlackRock Inc. raised its position in Curis by 2.3% in the 4th quarter. BlackRock Inc. now owns 9,719,497 shares of the biotechnology company’s stock valued at $6,803,000 after buying an additional 223,002 shares during the last quarter. Vanguard Group Inc. raised its position in Curis by 2.6% in the 2nd quarter. Vanguard Group Inc. now owns 4,955,068 shares of the biotechnology company’s stock valued at $9,365,000 after buying an additional 127,443 shares during the last quarter. Millennium Management LLC raised its position in Curis by 1,341.7% in the 4th quarter. Millennium Management LLC now owns 3,149,154 shares of the biotechnology company’s stock valued at $2,204,000 after buying an additional 2,930,725 shares during the last quarter. Finally, JPMorgan Chase & Co. raised its position in Curis by 62,201.8% in the 3rd quarter. JPMorgan Chase & Co. now owns 2,381,798 shares of the biotechnology company’s stock valued at $3,691,000 after buying an additional 2,377,975 shares during the last quarter. Hedge funds and other institutional investors own 48.14% of the company’s stock.
The company has a debt-to-equity ratio of 1.24, a quick ratio of 5.15 and a current ratio of 5.15.
ILLEGAL ACTIVITY WARNING: “Curis (CRIS) Sees Large Volume Increase After Earnings Beat” was first published by Ticker Report and is owned by of Ticker Report. If you are viewing this piece on another publication, it was stolen and reposted in violation of U.S. and international copyright and trademark laws. The original version of this piece can be viewed at https://www.tickerreport.com/banking-finance/3253911/curis-cris-sees-large-volume-increase-after-earnings-beat.html.
Curis Company Profile
Curis, Inc is a biotechnology company seeking to develop and commercialize drug candidates for the treatment of cancers. The Company’s drug candidate is CUDC-907, an orally-available, small molecule inhibitor of histone deacetylase (HDAC) and phosphatidylinositol-3-kinase (PI3K) enzymes. CUDC-907 is an oral, dual inhibitor of Class I and II HDAC, as well as Class I PI3K enzymes.
Receive News & Ratings for Curis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Curis and related companies with MarketBeat.com's FREE daily email newsletter.